Journal: BMC Pulmonary Medicine

Article Title: The relevance of sputum galectin-7 levels to clinical and prognostic factors in patients with chronic obstructive pulmonary disease: a prospective cohort study from China

doi: 10.1186/s12890-026-04171-9

Figure Lengend Snippet: Analysis of covariance (ANCOVA) of sputum galectin-7 levels among different groups (Healthy, GOLD I, GOLD II, GOLD III–IV), adjusted for age, sex, smoking status, smoking intensity and BMI

Article Snippet: Fig. 5 Sputum galectin-7 and future acute exacerbations in COPD: ( a ) comparison of baseline sputum galectin-7 levels between AECOPD and non-AECOPD groups; ( b ) prediction of future acute exacerbations using age, sex, smoking status, BMI, lung function, and other confounders, exacerbation history, and sputum galectin-7, with performance comparison between Multivariable Model 1 (confounders + galectin-7) and Multivariable Model 2 (confounders + exacerbation history) Fig. 6 Sputum galectin-7 and future frequent acute exacerbations in COPD: ( a ) comparison of baseline sputum galectin-7 levels between frequent AECOPD and non-frequent AECOPD groups; ( b ) prediction of future frequent acute exacerbations using age, sex, smoking status, BMI, lung function, and other confounders, exacerbation history, and sputum galectin-7, with performance comparison between Multivariable Model 1 (confounders + galectin-7) and Multivariable Model 2 (confounders + exacerbation history) To compare the predictive performance of sputum galectin-7 and a history of prior acute exacerbations for identifying patients at risk of future acute exacerbations, we constructed ROC models.

Techniques:

Journal: BMC Pulmonary Medicine

Article Title: The relevance of sputum galectin-7 levels to clinical and prognostic factors in patients with chronic obstructive pulmonary disease: a prospective cohort study from China

doi: 10.1186/s12890-026-04171-9

Figure Lengend Snippet: ROC curves of sputum galectin-7 for discriminating healthy controls from all COPD patients, healthy controls from GOLD I–II, healthy controls from GOLD III–IV, and GOLD I–II from GOLD III–IV

Article Snippet: Fig. 5 Sputum galectin-7 and future acute exacerbations in COPD: ( a ) comparison of baseline sputum galectin-7 levels between AECOPD and non-AECOPD groups; ( b ) prediction of future acute exacerbations using age, sex, smoking status, BMI, lung function, and other confounders, exacerbation history, and sputum galectin-7, with performance comparison between Multivariable Model 1 (confounders + galectin-7) and Multivariable Model 2 (confounders + exacerbation history) Fig. 6 Sputum galectin-7 and future frequent acute exacerbations in COPD: ( a ) comparison of baseline sputum galectin-7 levels between frequent AECOPD and non-frequent AECOPD groups; ( b ) prediction of future frequent acute exacerbations using age, sex, smoking status, BMI, lung function, and other confounders, exacerbation history, and sputum galectin-7, with performance comparison between Multivariable Model 1 (confounders + galectin-7) and Multivariable Model 2 (confounders + exacerbation history) To compare the predictive performance of sputum galectin-7 and a history of prior acute exacerbations for identifying patients at risk of future acute exacerbations, we constructed ROC models.

Techniques:

Journal: BMC Pulmonary Medicine

Article Title: The relevance of sputum galectin-7 levels to clinical and prognostic factors in patients with chronic obstructive pulmonary disease: a prospective cohort study from China

doi: 10.1186/s12890-026-04171-9

Figure Lengend Snippet: Spearman correlation heatmap of galectin-7 and clinical indicators . Red indicates positive correlations, and green indicates negative correlations, with color intensity reflecting correlation strength. Statistical significance is denoted as * P < 0.05, ** P < 0.01, and *** P < 0.001. Only correlations with P < 0.05 are labeled

Article Snippet: Fig. 5 Sputum galectin-7 and future acute exacerbations in COPD: ( a ) comparison of baseline sputum galectin-7 levels between AECOPD and non-AECOPD groups; ( b ) prediction of future acute exacerbations using age, sex, smoking status, BMI, lung function, and other confounders, exacerbation history, and sputum galectin-7, with performance comparison between Multivariable Model 1 (confounders + galectin-7) and Multivariable Model 2 (confounders + exacerbation history) Fig. 6 Sputum galectin-7 and future frequent acute exacerbations in COPD: ( a ) comparison of baseline sputum galectin-7 levels between frequent AECOPD and non-frequent AECOPD groups; ( b ) prediction of future frequent acute exacerbations using age, sex, smoking status, BMI, lung function, and other confounders, exacerbation history, and sputum galectin-7, with performance comparison between Multivariable Model 1 (confounders + galectin-7) and Multivariable Model 2 (confounders + exacerbation history) To compare the predictive performance of sputum galectin-7 and a history of prior acute exacerbations for identifying patients at risk of future acute exacerbations, we constructed ROC models.

Techniques: Labeling

Journal: BMC Pulmonary Medicine

Article Title: The relevance of sputum galectin-7 levels to clinical and prognostic factors in patients with chronic obstructive pulmonary disease: a prospective cohort study from China

doi: 10.1186/s12890-026-04171-9

Figure Lengend Snippet: Bidirectional comparison between emphysema and sputum galectin-7: ( a ) Emphysema Index in high, moderate, and low sputum galectin-7 groups; ( b ) Sputum galectin-7 levels (pg/mL) in participants with and without emphysema

Article Snippet: Fig. 5 Sputum galectin-7 and future acute exacerbations in COPD: ( a ) comparison of baseline sputum galectin-7 levels between AECOPD and non-AECOPD groups; ( b ) prediction of future acute exacerbations using age, sex, smoking status, BMI, lung function, and other confounders, exacerbation history, and sputum galectin-7, with performance comparison between Multivariable Model 1 (confounders + galectin-7) and Multivariable Model 2 (confounders + exacerbation history) Fig. 6 Sputum galectin-7 and future frequent acute exacerbations in COPD: ( a ) comparison of baseline sputum galectin-7 levels between frequent AECOPD and non-frequent AECOPD groups; ( b ) prediction of future frequent acute exacerbations using age, sex, smoking status, BMI, lung function, and other confounders, exacerbation history, and sputum galectin-7, with performance comparison between Multivariable Model 1 (confounders + galectin-7) and Multivariable Model 2 (confounders + exacerbation history) To compare the predictive performance of sputum galectin-7 and a history of prior acute exacerbations for identifying patients at risk of future acute exacerbations, we constructed ROC models.

Techniques: Comparison

Journal: BMC Pulmonary Medicine

Article Title: The relevance of sputum galectin-7 levels to clinical and prognostic factors in patients with chronic obstructive pulmonary disease: a prospective cohort study from China

doi: 10.1186/s12890-026-04171-9

Figure Lengend Snippet: Sputum galectin-7 and future acute exacerbations in COPD: ( a ) comparison of baseline sputum galectin-7 levels between AECOPD and non-AECOPD groups; ( b ) prediction of future acute exacerbations using age, sex, smoking status, BMI, lung function, and other confounders, exacerbation history, and sputum galectin-7, with performance comparison between Multivariable Model 1 (confounders + galectin-7) and Multivariable Model 2 (confounders + exacerbation history)

Article Snippet: Fig. 5 Sputum galectin-7 and future acute exacerbations in COPD: ( a ) comparison of baseline sputum galectin-7 levels between AECOPD and non-AECOPD groups; ( b ) prediction of future acute exacerbations using age, sex, smoking status, BMI, lung function, and other confounders, exacerbation history, and sputum galectin-7, with performance comparison between Multivariable Model 1 (confounders + galectin-7) and Multivariable Model 2 (confounders + exacerbation history) Fig. 6 Sputum galectin-7 and future frequent acute exacerbations in COPD: ( a ) comparison of baseline sputum galectin-7 levels between frequent AECOPD and non-frequent AECOPD groups; ( b ) prediction of future frequent acute exacerbations using age, sex, smoking status, BMI, lung function, and other confounders, exacerbation history, and sputum galectin-7, with performance comparison between Multivariable Model 1 (confounders + galectin-7) and Multivariable Model 2 (confounders + exacerbation history) To compare the predictive performance of sputum galectin-7 and a history of prior acute exacerbations for identifying patients at risk of future acute exacerbations, we constructed ROC models.

Techniques: Comparison

Journal: BMC Pulmonary Medicine

Article Title: The relevance of sputum galectin-7 levels to clinical and prognostic factors in patients with chronic obstructive pulmonary disease: a prospective cohort study from China

doi: 10.1186/s12890-026-04171-9

Figure Lengend Snippet: Sputum galectin-7 and future frequent acute exacerbations in COPD: ( a ) comparison of baseline sputum galectin-7 levels between frequent AECOPD and non-frequent AECOPD groups; ( b ) prediction of future frequent acute exacerbations using age, sex, smoking status, BMI, lung function, and other confounders, exacerbation history, and sputum galectin-7, with performance comparison between Multivariable Model 1 (confounders + galectin-7) and Multivariable Model 2 (confounders + exacerbation history)

Article Snippet: Fig. 5 Sputum galectin-7 and future acute exacerbations in COPD: ( a ) comparison of baseline sputum galectin-7 levels between AECOPD and non-AECOPD groups; ( b ) prediction of future acute exacerbations using age, sex, smoking status, BMI, lung function, and other confounders, exacerbation history, and sputum galectin-7, with performance comparison between Multivariable Model 1 (confounders + galectin-7) and Multivariable Model 2 (confounders + exacerbation history) Fig. 6 Sputum galectin-7 and future frequent acute exacerbations in COPD: ( a ) comparison of baseline sputum galectin-7 levels between frequent AECOPD and non-frequent AECOPD groups; ( b ) prediction of future frequent acute exacerbations using age, sex, smoking status, BMI, lung function, and other confounders, exacerbation history, and sputum galectin-7, with performance comparison between Multivariable Model 1 (confounders + galectin-7) and Multivariable Model 2 (confounders + exacerbation history) To compare the predictive performance of sputum galectin-7 and a history of prior acute exacerbations for identifying patients at risk of future acute exacerbations, we constructed ROC models.

Techniques: Comparison

Journal: Cellular and Molecular Gastroenterology and Hepatology

Article Title: Loss of Bile Salt Export Pump (Bsep/Abcb11) Ameliorates Toxin-induced Hepatic Fibrosis via Suppression of Hepatocellular Jun Amino-terminal Kinase Signaling and Hepatic Stellate Cell Activation

doi: 10.1016/j.jcmgh.2025.101630

Figure Lengend Snippet: Loss of Bsep improves CCl 4 -induced liver inflammation. ( A ) Representative MAC-2/Galectin3 IHC images (×10 magnification) as well as computational analysis show reduced numbers of macrophages in the livers of Bsep -/- mice. Real-time PCR was used to assess the mRNA expression of ( B ) Egr1 and its downstream targets ( C ) Cxcl1, Cxcl2, Ccl2, and Ccl5 as markers of inflammation. All of them were reduced in Bsep -/- mice subjected to CCl 4 treatment compared with WT mice. mRNA expression values were normalized against 36b4 levels and are shown relative to expression level in WT controls. ∗Significant difference from WT mice; # significant difference from WT CCl 4 mice; § significant difference from Bsep -/- mice; P < .05. Computational analysis of histological pictures was done via image J 1.51j8.

Article Snippet: Representative images of MAC-2/Galectin-3 immunohistochemistry (IHC) as well as computational analysis showed significantly less amounts of MAC-2 positive cells in liver of Bsep -/- mice subjected to CCl 4 in comparison to challenged WT animals ( A ). mRNA expression of Egr1 (a key driver of hepatic inflammation, and known to be induced via CCl 4 ) was increased in WT CCl 4 -challenged mice and remained unchanged in Bsep -/- mice upon CCl 4 challenge ( B ).

Techniques: Real-time Polymerase Chain Reaction, Expressing